Leptin deficiency produces a phenotype of obesity, diabetes, and infertility in the ob/ob mouse. In humans, leptin deficiency occurs in some cases of congenital obesity and in lipodystrophic disorders characterized by reduced adipose tissue and insulin resistance. Cutaneous gene therapy is considered an attractive potential method to correct circulating protein deficiencies, since gene-transferred human keratinocytes can produce and secrete gene products with systemic action. However, no studies showing correction of a systemic defect have been reported. We report the successful correction of leptin deficiency using cutaneous gene therapy in the ob/ob mouse model. As a feasibility approach, skin explants from transgenic mice overexpressing leptin were grafted on immunodeficient ob/ob mice. One month later, recipient mice reached body weight values of lean animals. Other biochemical and clinical parameters were also normalized. In a second human gene therapy approach, a retroviral vector encoding both leptin and EGFP cDNAs was used to transduce HK and, epithelial grafts enriched in high leptin-producing HK were transplanted to immunosuppressed ob/ob mice. HK-derived leptin induced body weight reduction after a drop in blood glucose and food intake. Leptin replacement through genetically engineered HK grafts provides a valuable therapeutic alternative for permanent treatment of human leptin deficiency conditions.-Larcher, F., Del Rio, M., Serrano, F., Segovia, J. C., Ramírez, A., Meana, A., Page, A., Abad, J. L., González, M. A., Bueren, J., Bernad, A., Jorcano, J. L. A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. FASEB J. 15, 1529 -1538 (2001) 
Leptin, the 16 kDa product of the OB gene, is an essential hormone secreted mainly by adipocytes that regulates food intake and neuroendocrine function via specific receptors in the hypothalamus (1, 2) . Experimental evidence suggests that leptin may also exert direct effects at the level of gene expression or cellular function on peripheral tissues including hematopoietic cells, T cells, the endocrine pancreas, pituitary, ovary, adipocytes, skeletal muscle, and hepatocytes (3, 4) . In addition, a role for leptin has recently been reported in angiogenesis and bone formation (5) (6) (7) .
Congenital leptin deficiency has been identified in humans and is associated with a rare, severe early-onset obesity (8, 9) . Recombinant leptin therapy is shown to lead to a sustained reduction in body weight in one of these patients, predominantly as a result of fat loss (10) .
Decreased circulating leptin levels are also reported in patients with different forms of generalized lipoatrophic diabetes (7) . Lipoatrophic diabetes designates a group of syndromes characterized by extreme paucity of adipose tissue, hyperglycemia, severe insulin resistance, hypoleptinemia, and voracious appetite (11, 12) . Other serious clinical features in the congenital form of the disease include an anabolic syndrome with organomegaly and hypertrophic cardiomyopathy. Since no causal therapy has yet been identified, a prophylactic approach is used in these patients based on a rigid control of calorie consumption and anabolic syndrome in order to delay diabetic complications and progression of hypertrophic cardiomyopathy (11) .
Leptin administration has recently been shown to increase glucose metabolism and restore insulin sensitivity in two transgenic mouse models of congenital generalized lipodystrophy (13) (14) (15) (16) , suggesting a critical role for leptin in the physiopathology of these disorders and its therapeutic potential for the treatment of human lipoatrophic diabetes.
Protein injection is frequently used to treat peptide hormone deficiencies. Although leptin has been deliv-ered by this route with good results in a patient suffering from leptin-deficient inherited obesity (10) , the treatment may be compromised by its short duration of action and the need for repetitive daily dosing. Gene therapy is thus an attractive alternative approach for leptin delivery and has received recent experimental support (17, 19) On the basis of their proliferative capacity and the proven value of cultured keratinocytes for skin wound coverage, autologous grafts of genetically engineered keratinocytes have been proposed as a suitable vehicle to correct for deficiencies in circulating proteins (20) . Previous studies have shown that the product of exogenous genes such as GH, factor IX, interleukin 6 (IL-6), etc., reach the blood circulation after being synthesized, processed, and secreted by gene-transferred human epidermal cells (21) (22) (23) (24) . In addition to these ex vivo approaches, transgenic mouse studies strongly support the concept of the epidermis as an efficient secretory bioreactor (25) (26) (27) .
A further boost to cutaneous gene therapy for systemic disorders has recently been provided. Partial correction of hemophilia A in factor VIII-deficient mice was achieved after grafting of factor VIII-expressing mouse skin from a loricrin factor VIII transgenic mouse (27) . Injection of plasmid DNA coding for IL-10 into rat skin also led to transient inhibition of contact hypersensitivity at a distant area of the skin (28) . To our knowledge, however, use of genetically modified human keratinocytes to correct for a systemic defect has not been described to date.
Here we report the successful correction of a leptin deficiency-derived metabolic disorder through cutaneous gene therapy using both murine and human keratinocytes. For this study, we used the obese ob/ob mutant mouse (29, 30) as a model of leptin deficiency. In these animals, the absence of leptin accounts for a dramatic phenotype characterized by extreme obesity due to increased food intake and low energy expenditure. Other clinical features include decreased immune function, infertility, and impaired wound healing. At the biochemical level, the ob/ob mice present hyperglycemia, hyperinsulinemia, and reduced levels of gonadotrophins (30) .
Skin grafts from a leptin-overexpressing skin transgenic mouse proved highly efficient for the correction of the ob/ob mouse systemic defect. This result led us to the development of a human cutaneous gene therapy-relevant approach. Thus, ex vivo leptin-transduced human keratinocyte (HK) grafts comprising less than 10% of the body surface corrected the leptin deficiency of ob/ob mouse. This is also the first study demonstrating successful replacement of a missing circulating protein using genetically modified human keratinocyte grafts.
MATERIALS AND METHODS

Animals
BALB/c CB17-Prkdc
scid and C57BL/6J ob/ob mice were purchased from IFFA-Credo-Charles River (St. Aulin-les-Elbeuf, France) and maintained at the CIEMAT Laboratory Animals Facility (Spanish registration number 28079 -21 A). Animals were housed in individually ventilated type II cages, maximum 4 mice each with 25 air changes per hour and 10 KGy gamma irradiated soft wood pellets as bedding. All handling was done under sterile conditions. All experimental procedures were carried out according to European and Spanish laws and regulations (European convention 123 about the use and protection of vertebrate mammals used in experimentation and other scientific purposes. Spanish R.D 223/88 and O.M. 13-10-89 of the Ministry of Agricultural, Food and Fisheries about the protection and use of animals in scientific research and internal biosafety and bioethics guidelines).
Generation of K5-leptin transgenic mice
A SmaI/NotI fragment from plasmid pOB1 containing the mouse leptin cDNA (a generous gift of Dr. M. Reitman, NIDDK, NIH) was blunted and inserted into a cassette containing the 5.2 kb bovine regulatory sequences, the 5Ј rabbit ␤-globin intron 2, and the 3Ј polyadenylation sequences (31, 32) . The construct was designated pK5-leptin. The transgene was excised from the plasmid pK5-leptin with NotI, purified by low melting point agarose electrophoresis and Elutip columns (Schleicher and Schuell, Keene, NH), adjusted to a final concentration of ϳ2 g/ml, and microinjected into (C57BL/6JϫDBA/2)F 2 mouse embryos as described (31, 32) . Founder mice were identified by Southern blot analysis of tail DNA using the 5.2 kb fragment corresponding to the bovine keratin K5 promoter as a probe. A detailed description of the characterization of K5-leptin transgenic mice will be reported elsewhere (F. Larcher et al., unpublished results).
Generation of graft recipient immunodeficient ob/ob mice
Fertile heterozygous ob/ϩ males were first mated with homozygous severe combined immunodeficiency SCID/SCID female mice (BALB/c CB-17 strain) to obtain double heterozygous SCID/ϩ, ob/ϩ animals. ob/ϩ mice were identified using the one-step PCR-based genotyping method described by Namae et al. (33) Double heterozygous SCID/ϩ, ob/ϩ males were crossed with female homozygous SCID/SCID mice to obtain immunodeficient ob/ϩ breeding pairs. Immunodeficiency was assessed by the absence of B and T lymphocytes in blood by FACS analysis using FITC-and PE fluorochrome-conjugated antibodies specific for murine B cells (anti-B220; Caltag, Burlingame, CA) and T cells (anti-CD3; BD-PharMingen, San Diego, CA), respectively, as described (34) . Finally, male and female immunodeficient heterozygous ob/ϩ mice pairs were bred to obtain immunodeficient ob/ob graft recipient obese mice, which developed at normal mendelian rates. A similar breeding strategy was attempted to obtain immunodeficient ob/ob mice on a nu/nu background with low efficiency.
Mouse skin grafts
Dorsal full-thickness skin pieces of 2-2.5 cm 2 were obtained from 5-to 7-wk-old K5-leptin transgenic mice or control littermates. Shaved donor skin pieces were grafted onto a wound created by removing a similar-sized piece of fullthickness back skin in female immunodeficient obese ob/ob recipient mice. Graft and host skin edges were joined using surgical silk suture and the grafted area was covered with a thin layer of NewSkin (Medtech, Jackson, WY) as the only protective dressing. This procedure allows graft-take monitoring and produced normal-haired donor skin.
Keratinocyte cell cultures and retroviral gene transfer
Human primary keratinocytes were obtained from newborn foreskins by repetitive trypsin incubation, then seeded on lethally irradiated 3T3-J2 cells (a gift from Dr. J. Garlick, SUNY) as described (35) . Retroviral infection was performed on small-sized cell colonies (8 -16 cells) of first-passage primary keratinocytes. Cells were incubated with pLZRS-leptin-IRES-EGFP or pLZRS-IRES-EGFP vector supernatants at a titer of 1 to 5 ϫ 10 6 CFU/ml for 4 h in the presence of polybrene (8 g/ml) on 2 consecutive days. Keratinocytes at 60 -80% confluence were trypsinized, resuspended in PBS/2% FCS, analyzed for EGFP expression and sorted by fluorescence-activated cell sorting on a FACStar PLUS flow cytometer (Becton Dickinson, San Jose, CA) as described (36) . Transduced, EGFP-sorted keratinocytes were seeded on live human fibroblast-containing fibrin gels at a density of 1 ϫ 10 4 cells/cm 2 . Fibrin-fibroblast gels were prepared according to Del Rio et al. (36) .
Mouse primary keratinocyte cultures from newborn K5-leptin transgenic animals or control littermates were obtained as described (32) .
Human keratinocyte grafts and immunosuppression of ob/ob mice
After reaching confluence, transduced human keratinocyte cultures on fibrin-fibroblast gels were manually detached, divided into 2-2.5 cm 2 squares, and grafted onto the dorsal region of female cyclosporin-A immunosuppressed ob/ob mice (one square/mouse) using the flap method described by Barrandon et al. (37) . Leptin-and control-transduced, EGFPsorted human keratinocyte composite cultures were grafted in five immunosuppressed mice, respectively. Mice were housed in pathogen-free conditions for the duration of the experiment. Grafting experiments were also performed in ob/ob mice with no immunosuppressive treatment.
Human-to-mouse xenografts were maintained in cyclosporin-A-treated ob/ob mice according to Compton et al., with minor modifications (38) . Animals received daily intraperitoneal injections of 25 mg/kg of cyclosporin-A (Sandimmum 50 mg/ml, Novartis, Summit, NJ) in a sterile olive oil suspension (200 l/mouse), starting 1 day before grafting and for the duration of the experiment (16 days).
Retroviral vector design and production
Retroviral expression vectors were constructed using the LZRS backbone vector (39, 40) . To construct the pLZRS-IRES-EGFP vector, a XhoI/NotI fragment containing the IRES and the EGFP gene was obtained from plasmid pIRES2-EGFP (Clontech, Palo Alto, CA) and cloned into the XhoI/NotI sites of plasmid pL3 to capture a BamHI site. The resulting construct was digested with BamHI and NotI, and the fragment of interest cloned into the BamHI/NotI sites of the retroviral vector backbone pLZRS-CMV-EGFP (kindly provided by Dr. G.P. Nolan, Stanford University, CA). To construct the pLZRS-leptin-IRES-EGFP vector, a BamHI/EcoRI fragment containing the mouse leptin cDNA obtained from plasmid pK5-leptin was cloned into the BamHI/EcoRI sites of pLZRS-IRES-EGFP vector plasmid. Defective retroviruses were generated through transient transfection of 293-T cells with packaging and retroviral vector plasmids according to Yang et al. (40) .
Glucose and leptin measurements
Blood samples were collected by tail incision. Blood glucose levels were determined between 9 and 10 am on nonfasted mice using a Gluco-touch digital monitor (Lifescan, Johnson & Johnson, Burnaby, B.C., Canada). Both serum and cultured keratinocyte-derived mouse leptin were determined using the Quantikine murine leptin ELISA kit (R&D Systems, Abingdon, Oxon, UK) following the manufacturer's instructions with minor modifications. Serum samples were assayed at 1:5-1:10 dilutions.
Animal weight and food intake
Body weight was measured every other day at the same time of day. For feeding studies, mice were placed in individual cages and acclimated to autoclaved standard rodent chow diet (A04, Panlab, Barcelona, Spain). A preweighed amount of diet was given per animal, and the difference in food weight after each time period provided a measure of food consumption.
Histology
Human keratinocyte graft recipient animals were killed at day 16 postgrafting. The graft-containing flap area was excised and tissue samples were formalin-fixed/paraffin-embedded for routine hematoxylin/eosin staining or frozen in OCT. Human involucrin immunostaining was performed on 5 m paraffin sections using the human-specific mouse monoclonal anti-involucrin antibody SY5 (Sigma, St. Louis, MO) at a 1:100 dilution. The ABC elite peroxidase kit (Dako, Carpinteria, CA) was used for antibody detection.
EGFP fluorescence was analyzed in unfixed 7 m frozen sections under the fluorescence microscope. Sections were mounted with Mowiol (Hoechst, Somerville, NJ) containing DAPI to stain nuclei.
Statistical analysis
Statistical significance was assessed by ANOVA with repeated measures analysis and Student's t test. All values are expressed as the mean Ϯ se.
RESULTS
Correction of the ob/ob phenotype using skin grafts from K5-leptin transgenic mice
To test the feasibility of using skin grafts containing genetically manipulated keratinocytes to correct the ob/ob mouse defect, we first developed transgenic mice overexpressing mouse leptin cDNA under the control of the bovine keratin K5 gene regulatory elements. As previously shown by our group and others, the 5.2 kb bovine K5 gene promoter enables high constitutive basal layer-specific expression of a wide variety of transgenes in the epidermis (31, 32, 41, 42) . In this case, transgenic epidermal cells were able to efficiently express, process, and secrete leptin resulting in very high serum leptin levels (105Ϯ13 ng/ml), leading to a more marked lean phenotype than that of the transgenic skinny mouse described by Ogawa et al. (43) . A detailed description of K5-leptin mice will be reported elsewhere (F. Larcher et al., unpublished results). Transplantation of 2-2.5 cm 2 shaved back skin pieces from K5-leptin mice to immunodeficient ob/ob mice induced complete correction of the obese phenotype (Figs. 1-4) . As early as 48 h after transplantation, a marked drop in blood glucose was observed. From day 5 postgrafting, all K5-leptin skin-grafted animals reached steady glucose levels comparable to those in lean (ϩ/? genotype) immunodeficient mice (151Ϯ13 mg/dl). In contrast, glucose remained at diabetic values throughout the experiment in animals transplanted with skin from control nontransgenic littermates (Fig.  1a) . K5-leptin skin-grafted ob/ob mice also showed a rapid decrease in food intake. After a postsurgical recovery period that affected both control skin-grafted and K5-leptin skin-grafted mice, food intake of K5-leptin skin-grafted animals stabilized at values approximately half that of controls (Fig. 1b) .
Sustained weight loss was apparent early after transplantation in K5-leptin skin-grafted mice, although weight loss kinetics changed with time. Whereas moderate weight decline occurred during the first days after transplantation, a more abrupt weight loss began around day 7, concomitant with hair regrowth in the graft (Fig. 2a) . This may be because the number of K5/leptin-expressing cells per area of skin increase during the anagen phase of hair follicle growth. On the contrary, control skin-grafted ob/ob mice started to regain weight after the slight weight loss, during the first 24 -48 h postgrafting. Recipient animals showed an average initial weight at grafting of 45.3 Ϯ 1.4 g. Five to six weeks after grafting, K5-leptin skin-transplanted mice lost 40% of body weight, reaching values within the range of age-and sex-matched lean immunodeficient littermates (ϩ/? genotype) (Fig. 2a) .
Complete reversion of leptin action after graft removal
One advantage of skin gene therapy lies in the possibility of graft excision in case of adverse reactions (44) . To determine the extent of reversibility of the graftdriven systemic response, we tested the effect of K5- Effect of K5-leptin skin graft on body weight of immunodeficient ob/ob recipient mice. a) Body weight of K5-leptin skin graft recipient mice was significantly lower than that of controls at all times after 7 days of grafting (PϽ0.05 and PϽ0.01 from day 11 postgrafting). Values are the mean Ϯ se and represent the percentage of body weight on the day of transplant (day 0). The average body weight for ob/ob mice at day 0 was 45.3 Ϯ 1.7 g. 34 days after the initial transplantation (arrow), K5-leptin skin grafts were excised and replaced by ob/ob mouse skin in two mice. b) 2 wk cumulative food intake in ob/ob recipient mice before (bars at left) and after K5-leptin skin graft removal (shaded bar in bars at right). leptin skin graft removal on 'slimmed' immunodeficient ob/ob mice. The K5-leptin skin graft was replaced with a size-matched skin piece from an ob/ob mouse donor. A sudden drop in circulating leptin after graft excision appeared to act as a strong starvation signal, and rapid weight gain was observed concomitant with the recovery of food intake that reached control skingrafted immunodeficient ob/ob values (Fig. 2a, b) . In contrast, immunodeficient ob/ob animals that conserved the K5-leptin skin graft remained within lean animal values (90 days after grafting, corresponding to the latest records; data not shown).
K5-leptin skin grafts produce stable serum leptin levels
Serum leptin was determined at different times postgrafting. K5-leptin skin-grafted mice showed values ranging from 3.1 to 4.5 ng/ml, a range within the physiological levels found in age-matched lean mice (Fig. 3) . The presence of stable serum leptin throughout the experiment indicates that the K5 promoter remains active in the graft. Serum leptin was undetectable in control skin-grafted mice. Thus, a contribution of the subcutaneous (s.c.) adipose tissue from the control skin graft to circulating leptin appears negligible. As predicted, animals that underwent K5-leptin skin graft removal showed an absence of serum leptin, as determined 5 days after graft excision (data not shown). Both a long-lasting corrective effect and a reversible effect on graft removal were the hallmarks of this transgenic approach. A representative sequence of experimental steps and changes in physical appearance is illustrated in Fig. 4 .
Correction of the ob/ob phenotype through ex vivo leptin-transduced human keratinocyte grafts
Having achieved efficient systemic leptin delivery from transgenic mouse keratinocytes, we sought a relevant ex vivo approach for human gene therapy.
Efficient leptin gene transfer into primary HKs was carried out with high-titer replication-defective retroviruses obtained through transient transfection in 293T cells (39, 40) . The retroviral construct (Fig. 5a ) contained an internal ribosome entry site (IRES) to coexpress leptin with EGFP as a selectable marker. The same construct lacking leptin cDNA was used to transduce control keratinocytes. Use of the IRES sequence in retroviral vectors for keratinocyte targeting has been described (45, 46) . To produce populations of entirely genetically engineered human keratinocytes before grafting, transduced cells were selected by EGFP sorting. This technique, previously used to select EGFP gene-transferred pig keratinocytes (36) , renders viable HK cells without affecting their capacity for growth and differentiation (M. Del 
Rio et al. unpublished observations). Sorted cells
were plated either on 3T3 feeder layer or on live fibroblast-containing fibrin gels (35, 36) , and their conditioned medium was assayed for murine leptin. Cells cultured on either substrate produced similar amounts of leptin (Fig. 5b) .
To predict the possible outcome of the experiment using leptin-transduced human epidermal cells, we compared in vitro leptin levels of transduced HKs with those of primary mouse keratinocyte cultures (MK) obtained from K5-leptin transgenic mouse. Leptintransduced HKs produced 30% more leptin than newborn K5-leptin mouse keratinocytes (357Ϯ31 vs. 255Ϯ35 ng/10 6 cells/24 h), suggesting that leptintransduced HKs should perform adequately as a leptin delivery source (Fig. 5b) .
Generation of immunodeficient ob/ob mice involves a long-term breeding process, since several rounds of heterozygote matings were required to obtain enough double mutant mice for use in these experiments (see Materials and Methods). To obtain an appropriate number of readily available animals, Figure 6 . Effect of leptin-transduced human keratinocyte grafts on blood glucose, food consumption and body weight on immunosuppressed ob/ob recipient mice. a) Glucose levels in leptin-transduced human keratinocyte graft recipients were significantly lower than controls at all times after 48 h of transplantation (PϽ0.01). b) Mice were caged individually and food intake was measured over a 48 h period. Values are the mean Ϯ se. P Ͻ 0.01 for ob/ob transplanted with leptintransduced HK grafts compared to ob/ob transplanted with control HK grafts 4 days after transplantation. c) Body weight of leptin-transduced human keratinocyte graft recipient mice was significantly lower than that of controls at all times after 2 days of grafting (P Ͻ 0.05 and PϽ0.01 after 6 days). Body weight is expressed as the percent of body weight on the day of transplant (day 0). The average body weight for immunosuppressed ob/ob mice at day 0 was 46.1 Ϯ 1.5 g. we performed the human xenotransplants on cyclosporin-A immunosuppressed ob/ob mice. Previous studies showed that cyclosporin-treated C57BL/6J mice accepted human keratinocyte xenografts for an average of 16 days (38), a period when a clear corrective response was observed with the K5-leptin skin grafts. Both control (IRES-EGFP) and leptin (leptin-IRES-EGFP)-transduced keratinocytes grown to confluence on fibrin-fibroblast gels were transplanted using an s.c. flap technique (36, 37) in cyclosporin-A immunosuppressed C57BL/6J ob/ob mice. A study of serum glucose levels and food intake showed a rapid corrective effect in the leptin-HK transplanted mice (Fig. 6a, b) . A drop in glucose within 48 h of transplantation was the first sign of keratinocyte-derived leptin action (Fig. 6a) . Food intake was markedly reduced in leptin-HK transplanted mice, and food intake measurements showed a 50% reduction compared with control-HK transplanted mice (Fig. 6b) . The rate of weight loss was rapid and sustained. At the end of the experiment (16 days after grafting), leptin-HK transplanted mice had lost an average of 30% of starting weight. In contrast, control HK-transplanted mice showed a moderate weight gain (Fig. 6c) . Serum leptin was determined at three different times throughout the experiment. Leptin levels were stable and ranged from 1.9 to 2.5 ng/ml (mean 2.20Ϯ0.24 ng/ml, nϭ5 at day five; 2.11Ϯ0.16 ng/ml at day 10, nϭ4; 2.10Ϯ0.21 ng/ml at day 15, nϭ4; Table 1 ). At day 16 postgrafting, animals were killed to analyze graft histopathology. Histological evaluation revealed a well-developed, healthy stratified epithelium of human origin, as determined by hematoxylin/eosin staining and specific human involucrin immunostaining (Fig. 7a, b) . Active gene expression was confirmed by EGFP fluorescence in the graft (Fig. 7c) . One of the leptin-HK-grafted animals showed a progressive loss of the phenotypic corrective effect starting around day 8 postgrafting (data not shown). Histological examination of the grafted area in this animal was consistent with T cell-mediated rejection (Fig. 7d) , indicating premature loss of the immunosuppressive treatment efficacy.
As also found for the K5-leptin grafts, a 2-2.5 cm 2 ex vivo genetically engineered HK graft sufficed to replace physiological leptin levels, which in turn reversed the ob/ob syndrome in a short-term experiment.
DISCUSSION
The majority of systemic protein deficiencies (i.e., type I diabetes, hemophilia, dwarfism) are currently treated by multiple injections of the deficient polypeptide. Safe administration procedures that would eliminate this unpleasant duty on the part of the patient would be highly desirable (19) . Somatic gene therapy offers an attractive alternative for permanent protein delivery. Numerous ex vivo, in vivo, and transgenic studies have established the potential therapeutic use of genetically manipulated keratinocytes as a noninvasive vehicle of circulatory systemic proteins (20 -27) .
Most studies of systemic keratinocyte gene therapy have emphasized critical issues such as duration of transgene expression and serum levels of the modified keratinocyte-derived proteins (47) (48) (49) . Less work has addressed the correction of circulating protein deficiencies. To date, only a partial corrective effect, in a mouse model of hemophilia A, has been achieved through grafts of involucrin factor VIII transgenic mouse skin (27) .
In the present study, we have been able to fully correct the phenotype of the leptin-deficient ob/ob mouse. When K5-leptin transgenic skin patches were grafted onto immunodeficient ob/ob mice, a rapid, lasting corrective effect was achieved as the clinical and biochemical parameters related to the obese phenotype returned to normal values. High serum leptin protein levels resulted from the basal cell-specific keratin K5 gene promoter activity. High hGH protein levels were similarly found in the blood of transgenic mice in which an hGH cDNA was under the control of the keratin K14 gene promoter (26) . The long-lasting effect achieved with the K5-leptin transgenic skin grafts reinforces the idea that the use of strong epidermal promoters would be a major asset to skin gene therapy. To be able to use gene constructs similar to those used in the generation of transgenic mice, however, improved nonviral gene transfer methods for human keratinocytes are still required (36) .
Transgenic approaches, although not of direct clinical relevance, allow us to address issues critical to modeling a therapeutic human ex vivo system, such as 1) whether the product of transferred genes can be delivered from epidermis to blood circulation, 2) to compare therapeutic protein concentrations in epidermal cell culture, 3) to make a rough estimate of the graft size needed, and 4) to assess potential undesired effects.
We used the K5-leptin transgenic skin grafting stud- ies to predict whether the ex vivo approach using genetically engineered human keratinocytes would be feasible. Differences in promoter specificity (viral LTRs vs. K5) and/or the presence of epidermal appendages, such as hair follicles in the transgenic mouse skin grafts, may lead to substantial variations in keratinocyte-derived leptin per area unit of grafted skin in vivo. In fact, although transduced and selected human keratinocytes produced 30% more bioactive leptin than keratinocytes derived from K5-leptin transgenic mice in vitro, serum leptin levels obtained with leptin HKs in vivo were slightly lower than predicted. Nevertheless, when grafts of leptin-producing human keratinocytes of similar size to those from K5-leptin mice were used, a rapid corrective effect was also achieved. Both the transgenic and ex vivo cutaneous gene therapy approaches reported here appear to be as efficient as another long-term delivery system in which a leptin-carrying adeno-associated virus is targeted to muscle in ob/ob mice (18) . Skin accessibility, ex vivo keratinocyte manipulation, and the possibility of graft removal highlight the feasibility as well as the safety advantages of this procedure over other gene therapy methods for leptin delivery. Both the immunosuppressive protocol and the grafting technique used allowed only a short-term study. We have nonetheless been able to show that ex vivo, genetically modified human keratinocyte grafts comprising less than 10% of total body surface were suitable for correction of leptin deficiency in mice. Some clinical and biochemical parameters of the ob/ob phenotype were not monitored during our corrective study. Based on previous studies of recombinant leptin administration and the fact that the serum leptin levels reached either after transgenic mouse skin or human keratinocyte grafts were within values found in lean animals, glucose, weight, and food intake appear to be representative markers of the complete ob/ob syndrome (50) . Experiments are under way to determine whether orthotopic grafting of genetically engineered leptinexpressing human keratinocytes are able to produce long-term correction in immunodeficient ob/ob mice. This goal appears within reach, considering the recent success in achieving sustainable gene expression in genetically engineered human keratinocytes (24, 49; M. Del Rio et al., unpublished results).
Obesity in humans is a major chronic disorder with a high incidence of morbidity; its molecular pathogenesis is the subject of intense study. Most obese individuals appear to be resistant to leptin, showing higher than normal levels of the hormone. In fact, inherited leptin deficiency appears to be a rare cause of extreme obesity in humans (8, 9) . Recombinant human leptin has been tested successfully on one such leptin-deficient patient (10) . Nonetheless, since leptin is a short half-life protein susceptible to breakdown and inactivation by the gastrointestinal system, daily s.c. injections need to be administered. It has become apparent that a group of patients suffering from some forms of lipodystrophy show reduced leptin levels (12) . Alleviation of severe insulin resistance after leptin administration has recently been shown in two transgenic mouse models of congenital generalized lipodystrophy (CGL) (13) (14) (15) (16) . CGL patients would thus probably benefit from leptin replacement. It is conceivable that, under experimental conditions equivalent to those described here, a single operation replacing less than 10% of the epidermal surface with leptin-producing keratinocyte sheets would suffice to restore normal leptin levels in patients suffering from leptin deficiency. Epidermal regeneration obtained with cultured keratinocytes has been shown to be long-lasting as well as life-saving in cases of severe wounds (51, 52) . In the last few years, cultured epidermal sheets bearing melanocytes have also been used to treat stable vitiligo with encouraging results; more important, new surgical procedures have been demonstrated that allow grafting without scarring (53) . These technical advantages and the feasibility of stable transduction of epidermal stem cells (24, 47, 48) lead us to predict a promising future for keratinocyte-mediated gene therapy for leptin and perhaps for other protein deficiencies.
